Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine, quantity: 15 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; lactose monohydrate; magnesium stearate; purified talc; hyprolose; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin; iron oxide yellow; iron oxide black; indigo carmine aluminium lake - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine, quantity: 20 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; lactose monohydrate; purified talc; microcrystalline cellulose; hyprolose; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin; iron oxide red; iron oxide yellow; iron oxide black - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 2.5 mg - oral olanzapine tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial [see clinical studies (14.1)].  when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)]. monotherapy — oral olanzapine tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with m

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 2.5 mg - oral olanzapine tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies (14.1)] . when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)] . monotherapy — oral olanzapine tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patie